Clinical Trial

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid Tumors
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-09.
Status change: Not Yet Recruiting → Recruiting 2026-01-13
Trial Details
NCT Number NCT07296341
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Locally Advanced or Metastatic Pancreatic Cancer With
Enrollment 60 participants
Start Date 2026-01-08
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-14